Mestag Therapeutics

Executive Summary

Mestag Therapeutics is a UK-based biotechnology company founded in 2020, pioneering the emerging field of fibroblast immunology. The company is developing first-in-class antibody therapies designed to modulate the critical interactions between fibroblasts and immune cells, with applications in both oncology and inflammatory diseases. Its pipeline includes bispecific and agonist antibodies aimed at either stimulating anti-tumor immunity or dampening overactive immune responses. Mestag operates in a highly innovative but competitive space, leveraging a deep understanding of fibroblast biology to address significant unmet medical needs.

Upcoming Catalysts (preview)

• Q4 2026Lead program IND application70% success
• Q3 2026Series B financing round60% success
• H2 2026Preclinical data presentation at major conference85% success